Cargando…

High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study

Detalles Bibliográficos
Autores principales:	Bennink, Christine, Westgeest, Hans, Schoonen, Daan, Boersen, Femke, Sonneveld, Pieter, Hazelzet, Jan, Blommestein, Hedwig, van der Klift, Marjolein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256370/ https://www.ncbi.nlm.nih.gov/pubmed/37304934 http://dx.doi.org/10.1097/HS9.0000000000000913

Ejemplares similares

Perspectives on returning to work of multiple myeloma patients: A qualitative interview study
por: Bennink, Christine, et al.
Publicado: (2021)

Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study
por: Bennink, Christine, et al.
Publicado: (2023)

Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice
por: Oerlemans, Simone, et al.
Publicado: (2020)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
por: Seefat, Maarten R., et al.
Publicado: (2021)

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
por: Blommestein, Hedwig M., et al.
Publicado: (2019)

Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)
por: Verelst, Silvia G.R., et al.
Publicado: (2018)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
por: Bennink, M. Christine, et al.
Publicado: (2022)

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands
por: Chen, Yi Hsuan, et al.
Publicado: (2023)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
por: Brink, Mirian, et al.
Publicado: (2022)

P53 REAL-WORLD TREATMENT SEQUENCES AND COSTS OF 96 PATIENTS WITH MULTIPLE MYELOMA FROM DIAGNOSIS TO DEATH
por: Seefat, M.R., et al.
Publicado: (2023)

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review
por: Chen, Yi Hsuan, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience
por: De Jong, Cornelis N., et al.
Publicado: (2017)

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
por: Bakker, LJ, et al.
Publicado: (2023)

Hospitalization at the end of life in patients with multiple myeloma
por: Abbasi, Saqib, et al.
Publicado: (2021)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?
por: Jongbloed, Elisabeth M, et al.
Publicado: (2023)

Real‐world evidence in health technology assessment of high‐risk medical devices: Fit for purpose?
por: Klein, Philip, et al.
Publicado: (2022)

Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
por: Ubels, Joske, et al.
Publicado: (2018)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma
por: Broijl, Annemiek, et al.
Publicado: (2021)

Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness
por: Neves, Manuel, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

COVID-19 AND MYELOMA
por: Ludwig, H, et al.
Publicado: (2022)

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
por: Cerchione, Claudio, et al.
Publicado: (2022)

Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome
por: van Beurden-Tan, Chrissy H. Y., et al.
Publicado: (2022)

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
por: Mutsaers, Pim, et al.
Publicado: (2021)

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
por: Engelhardt, Monika, et al.
Publicado: (2017)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
por: Ray, Upasana, et al.
Publicado: (2023)

Quality Improvement at an Academic Cancer Center: Venous Thromboembolism Prophylaxis in Patients With Multiple Myeloma
por: Baz, Rachid, et al.
Publicado: (2020)

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
por: Jagannath, Sundar, et al.
Publicado: (2023)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
por: Gay, Francesca, et al.
Publicado: (2018)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
por: Chen, Wendong, et al.
Publicado: (2016)

Trends in overall survival and costs of multiple myeloma, 2000–2014
por: Fonseca, R, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f1ro44jga26h0ao3p8ft9iuto8